Transluminal drug delivery methods and devices

a technology of transluminal drug delivery and delivery method, which is applied in the direction of prosthesis, biocide, heterocyclic compound active ingredients, etc., can solve the problems of inability to use oral anesthetic agents to inhibit urinary tract sensory nerve activation, limited treatment options for ic, and growing healthcare problems in the world

Inactive Publication Date: 2007-07-26
KALIUM
View PDF33 Cites 51 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0028](3) allowing the suppository to at least partially disintegrate and release the therapeutic agent and the buffering agent to treat at least a portion of the urinary tract of the patient.

Problems solved by technology

Diseases of the urinary tract present a growing healthcare problem worldwide.
Treatment options for IC are limited.
Although oral medications, such as pentosanpolysulfate (Elmiron®) and hyaluronic acid, are used to treat IC by replacing missing components in a defective glycosaminoglycan (GAG) barrier, a fundamental characteristic of IC, the use of oral anesthetic agents to inhibit urinary tract sensory nerve activation is impractical.
This effect may change the activity or function of the drug resulting in undesirable side effects or other co-morbidities.
However, existing modalities do not allow for an efficient absorption of some beneficial therapeutic agents.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Transluminal drug delivery methods and devices
  • Transluminal drug delivery methods and devices
  • Transluminal drug delivery methods and devices

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0134]Suppository Fabrication

[0135]Animal tests, using a New Zealand White rabbit model, were conducted to determine the safety profile of buffered lidocaine absorption by measuring plasma levels of lidocaine in the systemic circulation using different carrier bases. Levels of lidocaine that would be toxic if injected intravenously were fabricated in a suppository carrier base. Different carrier bases were warmed in a 40° C. base and lidocaine was added in increments of 10% of the final weight of the mixture until it reached a ratio of 3:7 lidocaine to carrier base. The pH of the mixture was measured after all lidocaine had dissolved using a temperature compensating pH meter. A 30% lidocaine mixture was found to be the highest concentration lidocaine mixture achievable with the carrier base materials that were tried. The mixture was raised to 70° C. in a water bath and titrated with sodium bicarbonate to a pH of 8.5 while the mixture was gently stirred. Heating and stirring were sto...

example 2

[0141]Human clinical studies were conducted to determine the efficacy of a buffered lidocaine suppository having a mucopolysaccharide component to repair any defect or injury to a luminal surface of a patient's urethra. A conical suppository with a weight of approximately 500 mg was used in the study. Suppositories were fabricated to contain approximately 10% lidocaine buffered to a pH of about 7.8. Methyl butyl ketone (MBK) was chosen as the suppository carrier base material, because the melting time of the base material could be adjusted by addition of paraffin to a melting time within a range of 5-15 minutes. Suppositories were fabricated with PEG but without any active ingredient to determine if the inflammatory response observed in the animals resulted in any adverse effects in humans. Suppositories containing PEG carrier base materials were placed in two human subjects with both subjects complaining of urethral burning and urinary frequency. As a result, PEG was not used clini...

example 3

[0144]The study of Example 3 investigates the amount of sodium bicarbonate necessary to buffer a lidocaine solution to a pH of 7.6-7.8. Sodium bicarbonate in 3 mg increments was added to three concentrations of lidocaine in two volumes of water. The three concentrations of lidocaine were 30, 45, and 60 mg. The rationale for this choice of lidocaine concentrations was they represent a 5-12% range of lidocaine concentrations, by weight, in the 500 mg suppository expected to be used in future clinical studies. This range of lidocaine concentrations in the suppository covers what will most likely be the lidocaine concentration used in the final clinical version of a buffered lidocaine suppository.

[0145]To measure pH, the lidocaine and sodium bicarbonate must be dissolved in solution. However, lidocaine and sodium bicarbonate are not dissolved in the suppository. Rather, they are in suspension in the carrier base and dissolve only after they are released from the carrier base and exposed...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
weightaaaaaaaaaa
weightaaaaaaaaaa
lengthaaaaaaaaaa
Login to view more

Abstract

Transluminal drug delivery method and device embodiments can include a urethral suppository formulated to prevent or treat diseases of the urethra and surrounding organs, such as interstitial cystitis or urethritis, by enhancing the absorption of a therapeutic agent of the suppository into body tissues without adversely affecting the natural defense mechanisms of these tissues. Adverse effects on the glycosaminoglycan (GAG) barrier can be mitigated or eliminated by the presence of a suitable polysaccharide in the suppository.

Description

CROSS-REFERENCES[0001]This application is a continuation-in-part application of U.S. patent application Ser. No. 11 / 340,071 by Zupkas et al., entitled “Transluminal Drug Delivery Methods and Devices,” filed on Jan. 26, 2006, and incorporated herein in its entirety by this reference.BACKGROUND OF THE INVENTION[0002]Diseases of the urinary tract present a growing healthcare problem worldwide. One of the most common diseases of the urinary tract is interstitial cystitis. Interstitial cystitis (IC) is a clinical syndrome of frequency, urgency, and / or pelvic pain in the absence of any definable pathology, such as urinary infection, carcinoma, or cystitis induced by radiation or medication. A diagnosis of IC is often reached as a diagnosis of exclusion, where patients have tried treatments for other diseases exhibiting similar symptoms and those treatments have failed to alleviate the symptoms. The disease is best understood as a continuum, with an early phase in which symptoms are interm...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K31/737A61K31/728A61K31/727A61K31/46A61K31/24
CPCA61K9/0034A61K9/02A61K31/167A61K31/24A61K9/025A61K31/728A61K31/737A61K31/727A61K2300/00
Inventor ZUPKAS, PAULPARSONS, C. LOWELL
Owner KALIUM
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap